A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

Conditions: Oculopharyngeal Muscular Dystrophy Interventions: Genetic: BB-301: Dose escalation phase 1b cohort 1; Genetic: BB-301: Dose escalation phase 1b cohort 2; Genetic: BB-301: Dose escalation phase 1b cohort 3; Genetic: BB-301: Dose expansion phase 2a Sponsors: Benitec Biopharma, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials